Please ensure Javascript is enabled for purposes of website accessibility

Red Light, Green Light: 2 Things to Know Before Buying Teva Pharmaceutical Industries Ltd (ADR) Stock

By Max Macaluso – Jan 9, 2014 at 12:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

What do investors need to know before investing in drugmaker Teva?

Shares of drugmaker Teva (TEVA 3.16%) stumbled in 2013, finishing the year far behind the S&P 500.

TEVA Total Return Price Chart

TEVA Total Return Price data by YCharts

Today, however, this stock trades at an attractive multiple and could be set for a rebound in 2014. But is it smooth sailing ahead for this unique drugmaker, or are there challenges in the coming years that should worry investors? Analyst Max Macaluso explores this stock in the following video and presents one reason to avoid Teva and one reason to be optimistic about the stock's future.

Editor's Note: At 2:37, Max meant to say Teva appointed "Erez Vigodman."

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.